AstraZeneca Finds Another Jewel in China With Up To $2B For KRAS Inhibitor

By /

Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.

Scroll to Top